v3.26.1
Consolidated Statements of Cash Flows
 12 Months Ended
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Cash flows from operating activities    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ (15,189,000) $ (4,347,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock option compensation expense 2,965,000 2,063,000
Common stock issued for services 648,000 416,000
Credit loss expense 3,886,000 13,000
Operating lease right-of-use assets amortization 148,000 100,000
Finance lease right -of-use asset amortization 113,000 0
Operating lease liabilities, net (137,000) (82,000)
Finance lease liability, net (88,000) 0
Interest expense related to amortization of the discount on note payable 196,000 0
Fair value of warrants issued for a fee and interest 0 106,000
Loss on investment in South Korean joint venture 14,000 5,000
PPP forgiveness 0 (97,000)
Depreciation expense 145,000 155,000
Changes in assets and liabilities:    
Accounts receivable (1,814,000) (569,000)
Inventories 20,000 (177,000)
Prepaid expenses and other assets (226,000) (58,000)
Deposits 99,000 (27,000)
Contract liabilities 280,000 (303,000)
Net cash used in operating activities (8,297,000) (3,206,000)
Cash flows from investing activities    
Equipment purchases (46,000) (1,235,000)
Clyra Medical note receivable 0 (82,000)
Repayment of note receivable 481,000 0
Net cash provided by (used in) investing activities 435,000 (1,317,000)
Cash flows from financing activities    
Proceeds from sale of common stock, net of offering costs 2,027,000 594,000
Proceeds from BioLargo stock option exercise 0 153,000
Proceeds (repayments) from debt obligations, net 24,000 (14,000)
Net cash provided by financing activities 8,221,000 4,438,000
Net change in cash 335,000 9,000
Cash at beginning of year 3,548,000 3,539,000
Cash at end of year 3,883,000 3,548,000
Net effect of foreign currency translation (24,000) 94,000
Supplemental disclosures of cash flow information    
Interest 344,000 33,000
Income taxes 0 0
Short-term lease payments not included in lease liability 51,000 49,000
Non-cash investing and financing activities    
Conversion of accounts receivable to a note receivable 3,764,000 0
Clyra preferred series A dividend 347,000 345,000
Conversion of debt into shares of BioLargo common stock 250,000 0
Conversion of BETI common sotck to BioLargo common stock 25,000 0
Fair value of warrants issued with Clyra Medical note payable 231,000 160,000
Present value of new Clyra Medical right-of-use asset and operating lease liability 184,000 0
Present value of new financing right of use and lease liability 0 451,000
Allocation of noncontrolling interest 2,649,000 993,000
Conversion of Debt into Shares of Common Stock [Member]    
Non-cash investing and financing activities    
Conversion of debt into shares of BioLargo common stock 0 119,000
Clyra Medical Common Stock [Member]    
Cash flows from financing activities    
Proceeds from sale of common stock, net of offering costs 445,000 2,005,000
BETI Common Stock [Member]    
Cash flows from financing activities    
Proceeds from sale of common stock, net of offering costs 425,000 50,000
BioLargo Energy Technologies, Inc (BETI) [Member]    
Cash flows from financing activities    
Proceeds from BioLargo warrant exercise 0 756,000
Clyra Medical Technologies [Member]    
Cash flows from financing activities    
Proceeds from BioLargo warrant exercise 1,894,000 30,000
Entities, Excluding Partially Owned Subsidiary [Member]    
Changes in assets and liabilities:    
Accounts payable and accrued expenses 266,000 (542,000)
Partially Owned Subsidiary [Member]    
Changes in assets and liabilities:    
Accounts payable and accrued expenses 377,000 138,000
Cash flows from financing activities    
Proceeds from sale of preferred stock in Clyra Medical 2,145,000 0
Proceeds from Clyra Medical note payable $ 1,261,000 $ 864,000